ourcimn	la stans i	to cuhmi	it your rei	Forral
our simp	ie steps i	to subili	it your rei	Cirai.

	If NP or PA, under direction of Dr.
	Office contact and title
Patient's first name	Office contact phone Office contact e-mail
Last name Middle initial	Office/clinic/institution name
Date of birth 🛛 Male 🖵 Female Last 4 digits of SSN	Clinic/hospital affiliation
Street address Apt #	Street address Suite #
	CityStateZip
City State Zip	Phone Fax
Home phone Cell phone E-mail	NPI # License # Deliver product to: Office
Parent/guardian (if applicable)	
Home phone Cell phone E-mail	Clinic location
Alternate caregiver/contact	3 CLINICAL INFORMATION
Home phone Cell phone E-mail	Diagnosis: Please identify both: 1) the primary diagnosis being treated with Droxidopa and 2) the symptomatic condition being treated with Droxidopa.
□ OK to leave message with alternate caregiver/contact	1) Primary diagnosis:
Patient's primary language:	G20 Parkinson's Disease G90.9 Disorder of the autonomic nervous system, unspecified
	G99.0 Autonomic neuropathy in diseases classified elsewhere
Please attach copies of front and back of the patient's medical and prescription insurance cards.	G90.3 Multi-system degeneration of the autonomic nervous system
Insurance company	□ Other
	2) Symptomatic condition:
Phone	Neurogenic orthostatic hypotension (currently no nOH-specific ICD-10 exists)
Insured's name	□ 195.1 Orthostatic hypotension □ 195.89 Other hypotension □ R55 Syncope and collapse
Insured's employer	□ R42 Dizziness and giddiness □ Other
Relationship to patient	Check all that apply: □ Failure or inadequate response to nonpharmacologic therapy.
Identification #	Therapy Name
Policy/group #	□ Failure □ inadequate response □ contraindication or □ intolerance to fludrocortisone
Prescription card: 🗆 Yes 🗅 No If yes, carrier	□ Failure □ inadequate response □ contraindication or □ intolerance to midodrine
Policy # Group #	Patient weight (kg) Date of weight
Is patient eligible for Medicare? 🗆 Yes 📮 No	NKDA Drug and non-drug allergies Concurrent meds
Does patient have a secondary insurance? 🗆 Yes 🕒 No	

4 PRESCRIBING INFORMATION

STARTER DOSE					
Medication	Strength/Formulation	Directions	Quantity/Refills		
Droxidopa	100mg capsules	Take 100mg by mouth three times a day then increase dose by 100mg per dose every days. Take last dose at least 3 hours before bedtime.	Dispense: 30-day supply Other Refills: 0		
□ Northera® (droxidopa)	100mg capsules	Take 100mg by mouth three times a day then increase dose by 100mg per dose every days. Take last dose at least 3 hours before bedtime.	Dispense: I 30-day supply Other Refills: 0		

Prescriber's first name

Prescriber's title

All fields must be completed to expedite prescription fulfillment.

Date medication needed

Last name

• Titrate to a symptomatic response. Maximum daily dose required will vary by individual. • Monitor supine blood pressure prior to initiating Northera and after increasing the dose. Max dose is 600 mg TID.

Medication	Strength/Formulation	Directions	Quantity/Refills
□ Droxidopa	 100mg 200mg 300mg Other dose than listed above: morning, noon and afternoon 	Takeby mouth three times a day. Take last dose at least 3 hours before bedtime.	Dispense: 30-day supply 90-day supply Other Refills:
□ Northera® (droxidopa)	□ 100mg □ 200mg □ 300mg □ Other dose than listed above: morning, noon and afternoon	Takeby mouth three times a day. Take last dose at least 3 hours before bedtime.	Dispense: a 30-day supply 90-day supply Other Refills:

Please fax completed form to 888.302.1028. To reach your team, call toll-free 844.412.4764.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents. All rights in the product names, take anames or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. © 2021 Accredo Health Group, Inc. | An Express Scripts Company. All rights reserved. AHG-00481-041521CRP2104_008600.1